

## Menopause: diagnosis and management (update) Advisory Committee Interests Register

Register last updated: 12/04/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Anita Sharma	Committee member	Direct – financial	GP with special interest in women’s health, GP triager of gynaecology referrals, GP Trainer and appraiser, South Chadderton Health Centre, Oldham	Interest arose more than 12 months before appointment	During recruitment	Ongoing	Member’s paid employment Declare and participate Agreed by GL and GC November 2022 Rationale: Salaried employment in the NHS. This interest is non-specific.
Dr Anita Sharma	Committee member	Direct – financial	Presentation on Diagnosis and management of menopause in Edenfield Road Surgery Rochdale—GPs, PN, ANP, Pharmacist.  Case discussion, how to manage shortage of recent HRT products. Guidance to check BMS (British Menopause Society) regarding shortage of creams and what action to take.  Sponsored by Viatrix	12.05.2022	17.05.2022	12.05.2022	Declare and participate. Agreed by developer Guideline Lead in May 2022. Rationale: Although broadly related to the topic, not specific to the scope of the guideline update.

Dr Anita Sharma	Committee member	Direct – financial	<p>Presentation MIMS Learning LIVE London</p> <p>Diagnosis and management of menopause. I will guide them to check BMS regularly to keep up to date about shortage of products and what action to take.</p> <p>No mentioning of which products to use.</p> <p>Sponsored by Theramex</p>	10.06.2022	15.05.2022	10.06.2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in May 2022.</p> <p>Rationale: Although broadly related to the topic, not specific to the scope of the guideline update.</p>
Dr Anita Sharma	Committee member	Direct – financial	<p>Online presentation for primary care (GPs, PN, ANP) on Diagnosis and Management of menopause.</p> <p>Continuous combined and sequential combined and estrogen alone HRT, which contraceptive to use (COC, POP, DEPO, coil), how often to do the monitoring, contraindications of HRT, which blood tests to do, why and when? Is USS necessary to make a diagnosis of menopause? How to manage POI? No mention of any products.</p> <p>Sponsored by Viatrix</p>	19.03.2022 & 04.05.2022	15.05.2022	19.03.2022 & 04.05.2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in May 2022.</p> <p>Rationale: Although broadly related to the topic, not specific to the scope of the guideline update.</p>
Dr Anne Armstrong	Co-opted member	Direct financial	Consultant Medical Oncologist and Honorary Senior Lecturer,	Interest arose more than 12	During recruitment	Ongoing	Member's paid employment

			Medical Oncology, The Christie Hospital NHS Foundation Trust, Manchester	months before appointment			Declare and participate  Agreed by GL and GC November 2022  Rationale: Salaried employment in the NHS. This interest is non-specific.
Dr Anne Armstrong	Co-opted member	Direct – financial	Private Practice: Breast Oncologist, The Christie Clinic, Manchester. 0.5-1 sessions per peer as a breast oncologist, mirrors NHS work.	2011	08.03.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: Not menopause specific and practice mirrors NHS work. Little possibility for financial gain to the member and thus her private practice was not considered to pose a conflict of interest.
Dr Anne Armstrong	Co-opted member	Indirect	Spousal Shares Astra Zeneca	March 1996	08.03.2022	03/2020	Declare and participate.  Agreed by developer Guideline Lead and

							NICE Clinical Advisor at recruitment.  Rationale: Spouse no longer owns the shares.
Dr Anne Armstrong	Co-opted member	Direct – financial	Advisory Board, MSD	November 2021	08.03.2022	11/2021	Declare and participate.  Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: Interest has ceased.
Dr Anne Armstrong	Co-opted member	Direct – financial	Advisory Board, Gilead	May 2021	08.03.2022	02/2022	Declare and participate.  Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: Interest has ceased.
Dr Anne Armstrong	Co-opted member	Direct – non-financial professional	Co-Chair, NCRI Breast Symptom Management Subgroup	March 2018	08.03.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead and

		and personal interests					NICE Clinical Advisor at recruitment. Rationale: Not specific to guideline.
Dr Anne Armstrong	Co-opted member	Direct – non-financial professional and personal interests	Clinical Lead, RCOG Guideline Group, Pregnancy and Breast Cancer	April 2020	08.03.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment. Rationale: Not specific to guideline.
Dr Anne Armstrong	Co-opted member	Direct – non-financial professional and personal interests	Chief Investigator: Personalised Electronic Record Supported two-stage observational study of sleep-in patients with breast cancer (sponsor Closed Loop Medicine)	September 2021	08.03.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment. Rationale: Not specific to guideline.
Dr Anne Armstrong	Co-opted member	Direct – non-financial professional and personal interests	Breast Cancer Expert Advisor for FDA submission for insomnia product (CLM)	March 2022	08.03.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical

							Advisor at recruitment. Rationale: Not specific to guideline.
Dr Anne Armstrong	Co-opted member	Direct – non-financial professional and personal interests	Studies in development (not funded): <ul style="list-style-type: none"> <li>• Topical estrogen for treatment of urogenital atrophy after breast cancer</li> <li>• Interventional study of drug+app for insomnia after breast cancer (sponsor CLM)</li> </ul>	n/a (not funded yet)	08.03.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment. Rationale: Studies not yet active or funded. The first topic may be of relevance to the guideline, however, in early stages.
Dr Anne Armstrong	Co-opted member	Indirect interests	Research Funding Astra Zeneca for development of a decision support tool for breast cancer	August 2021	08.03.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment. Rationale: Not specific to guideline.

Dr Anne Armstrong	Co-opted member	Indirect interests	Research Funding Breast Cancer Now for pre-operative window trial  Impala: Immunological effects of Avelumab and Aspirin in Triple Negative Breast Cancer.	Dec 2017	08.03.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: Not specific to guideline.
Dr Anne Armstrong	Co-opted member	Indirect interests	Research Funding JP Molton for pan-tumour trial of celecoxib in metastatic breast, renal and lung cancer.  LION: Lifting Immune Checkpoints with NSAIDs.	March 2020	08.03.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: Not specific to guideline.
Dr Anne Armstrong	Co-opted member	Indirect interests	Principal and Local Co-ordinating Investigator for therapy trials for patients with early and metastatic breast cancer	2007	08.03.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: Not specific to guideline.

Professor David Armstrong	Co-opted member	Direct – financial	I have received several payments for Advisory Board work from UCB Pharma, who manufacture a medicine for osteoporosis, although not one directly linked with HRT or the menopause	2020	24.02.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment. Rationale: Not specific to guideline.
Professor David Armstrong	Co-opted member	Direct - financial	Consultant rheumatologist & osteoporosis specialist, Western Health and Social Care Trust, Londonderry, Northern Ireland	Interest arose more than 12 months before appointment	During recruitment	Ongoing	Member's paid employment Declare and participate Agreed by GL and GC November 2022 Rationale: Salaried employment in the NHS. This interest is non-specific.
Professor David Armstrong	Co-opted member	Direct – financial	I have until recently owned stock in GlaxoSmithKline who previously made a drug used to treat osteoporosis	2000	24.02.2022	2022	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.

							Rationale: Member no longer owns the stock.
Professor David Armstrong	Co-opted member	Direct – financial	I have received several payments for educational presentations to GPs on the use of vitamin D and the management of osteoporosis from Internis Pharma Ltd, who manufacture and sell a vitamin D product	2013	24.02.2022	2020	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment. Rationale: Not specific to guideline.
Professor David Armstrong	Co-opted member	Direct – non-financial professional and personal interests	I am Vice Chair of the Clinical Committee of the Royal Osteoporosis Society, which advises the charity on clinical matters	2015	24.02.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment. Rationale: Not specific to guideline.
Professor David Armstrong	Co-opted member	Direct – non-financial professional and personal interests	I am a member of the Expert Advisory Group of NOGG, which produces guidelines on osteoporosis management	2019	24.02.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.

							Rationale: Not specific to guideline.
Professor David Armstrong	Co-opted member	Direct – non-financial professional and personal interests	I am a Visiting Professor and Supervisory Board member for the Nutrition Innovation Centre for Food and Health, Ulster University, which advises on research and student teaching on nutrition, including work on bone health and women’s health	2019	24.02.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment. Rationale: Not specific to topics covered in the guideline update.
Professor David Armstrong	Co-opted member	Direct - financial	Further payment from UCB Pharma for speaking and chairing meeting discussing the use of romosozumab, a drug for osteoporosis	March 2023	20.03.2023	March 2023	Declare and participate. Agreed by developer Guideline Lead and Committee Chair March 2023. Rationale: Not specific to guideline.
Professor Eef Hogervorst	Co-opted member	Direct - financial	Professor of Biological Psychology, Loughborough University	Interest arose more than 12 months before appointment	During recruitment	Ongoing	Member’s paid employment Declare and participate Agreed by GL and Chair November 2022

							Rationale: Salaried employment in the public sector. This interest is non-specific.
Professor Eef Hogervorst	Co-opted member	Direct – financial	I was paid as PhD student to provide a review for Organon with my supervisor	1996	07.03.2022	1997	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment. Rationale: Historic interest.
Professor Eef Hogervorst	Co-opted member	Direct – financial	I was paid by Wyeth to attend an expert meeting to explain WHI results	2002	07.03.2022	2002	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment. Rationale: Historic interest.
Professor Eef Hogervorst	Co-opted member	Direct – non-financial professional and personal interests	Various academic publications (earlier than 2005 not included here): Hogervorst, E., Craig, J., & O'donnell, E. (2021). Cognition and mental health in menopause:		07.03.2022	N/A	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical

			<p>A review. Best practice &amp; research. Clinical obstetrics &amp; gynaecology.</p> <p>Hogervorst, E., Craig, J., &amp; O'donnell, E. (2021). Cognition and mental health in menopause: A review. Best practice &amp; research. Clinical obstetrics &amp; gynaecology.</p>	2021			<p>Advisor at recruitment.</p> <p>Rationale: Topics may be relevant to the guideline on a general level but unlikely to be included in the evidence reviews.</p>
			<p>Hogervorst E. Oophorectomy and hysterectomy may increase dementia risk but only when performed prematurely. J Alzheimers Dis. 2014;42(2):583-6.</p>	2021			
			<p>European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016 May;31(5):926-37. Doi: 10.1093/humrep/dew027. Epub 2016 Mar 22. PMID: 27008889.</p>	2014			
				2016			

			Hogervorst E. Effects of gonadal hormones on cognitive behaviour in elderly men and women. J Neuroendocrinol. 2013 Nov;25(11):1182-95. Doi: 10.1111/jne.12080. PMID: 23895362.	2013			
			Hogervorst, E. (2013) Estrogen and the brain: does estrogen treatment improve cognitive function? Invited review for special issue Menopause International19 (1), 6-19 (IF 2.97)	2013			
			Hogervorst. E. & Bandelow, S. Sex steroids to maintain cognitive function in women after the menopause: A meta-analyses. Maturitas, 2010 May; 66(1) 56-71 Invited (IF2.94)				
			Hogervorst, E., Matthews, F.M., Brayne, C. (2010). Are optimal levels of testosterone associated with better cognitive function in healthy elderly women and men? Biochim Biophys Acta. 2010 Oct;1800(10):1145-52. Invited for special issue (IF 4.62)	2010			
			Hogervorst E, Bandelow S. Brain and cognition. Is there any case for improving cognitive function in menopausal women using estrogen treatment? Minerva				

			Ginecol. 2009 Dec;61(6):499-515. PMID: 19942838.	2009			
			Hogervorst, E., Yaffe, K., Richards, M., Huppert, F.A. (2009) Hormone replacement therapy to maintain cognitive function in women with dementia-update. Cochrane-Database-Syst-Rev. (2): CD003799.	2009			
			Kalaria, RN. Et al (including Hogervorst E. for the World Federation of Neurology Dementia Research Group) AD and VaD in developing countries: prevalence, management, risk factors. Lancet Neurol 2008 (IF 10.2)	2008			
			Rodrigues MA, Verdile G, Foster JK, Hogervorst E, Joesbury K, Dhaliwal S, Corder EH, Laws SM, Hone E, Prince R, Devine A, Mehta P, Beilby J, Atwood CS, Martins RN. Gonadotropins and cognition in older women. J Alzheimers Dis. 2008 Apr;13(3):267-74. Doi: 10.3233/jad-2008-13304. PMID: 18430994.	2008			
			Lethaby, A, Hogervorst, E., Richards, M., Yesufu, A., Yaffe, K. (2008) HRT for cognitive function in postmenopausal				

			women. Cochrane review update Jan 23;(1):CD003122.  Hogervorst, E & Bandelow S (2007) Should surgically menopausal women be treated with estrogens to decrease the risk for dementia? Invited Editorial Neurology 69 (11), pp.1070-1071 (IF 5.97)	2008  2007			
Professor Eef Hogervorst	Co-opted member	Direct – non-financial professional and personal interests	I work for Women in Higher Education network to give lectures (unpaid) and develop a course (paid for my time) on menopause information and management on the basis of my 15 independent reviews.	2020	07.03.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: Unpaid lectures, unlikely to have an impact on the guideline recommendations.
Professor Eef Hogervorst	Co-opted member	Direct – non-financial professional and personal interests	I was asked to give my opinion on the Channel 4 Documentary Sex Mind and the Menopause in the Conversation:  <a href="https://theconversation.com/menopause-hrts-brain-protecting-effect-may-be-overstated-182449">https://theconversation.com/menopause-hrts-brain-protecting-effect-may-be-overstated-182449</a>	May 2022	16.05.2022	N/A	Declare and participate.  Agreed by developer Guideline Lead in May 2022.  Rationale: Potential overlap with topics covered in the guideline scope,

							however, not considered to pose a conflict of interest. Views expressed in the article are based on the member's previous systematic reviews.
Professor Eef Hogervorst	Co-opted member	Direct – non-financial professional and personal interests	Gave public lectures on menopause and the brain for University: Manchester university, Lboro University	14.06.2022	11.07.2022	14.06.2022	Declare and participate. Agreed by developer Guideline Lead Rationale: Potential overlap with one of the topics covered in the guideline scope, however, not considered to pose a conflict of interest because it is a lecture about general aspects related to menopause and the brain rather than specifically on hormone replacement therapy.
Professor Eef Hogervorst	Co-opted member	Direct – non-financial	Wrote a piece in the conversation	10.06.2022	11.07.2022	10.06.2022	Declare and participate.

		professional and personal interests	<a href="https://theconversation.com/menopause-hrts-brain-protecting-effect-may-be-overstated-182449">https://theconversation.com/menopause-hrts-brain-protecting-effect-may-be-overstated-182449</a>				<p>Agreed by developer Guideline Lead in September 2022</p> <p>Rationale: Potential overlap with one of the topics covered in the guideline scope, however, not considered to pose a conflict of interest because it outlines some of the arguments related to potential effects of hormone replacement therapy on the brain but does not make a definitive statement on the impact on clinical practice.</p>
Professor Eef Hogervorst	Co-opted member	Direct – non-financial professional and personal interests	Did an interview in June 2022 for beingpatientbraintalks on my previous HRT and cognition literature review and the article we published in the Conversation (see earlier DOI) on the possibly short lived effects of HRT on brain function	14 June 2022 Online 20 July 2022	20.03.2023	On YouTube As a transcript online	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair in March 2023.</p> <p>Rationale: Whilst this is relevant to the scope of the guideline the review this was based on</p>

							was not included in the evidence review and therefore the talk was not specific to the topic under discussion.
Professor Eef Hogervorst	Co-opted member	Direct – non-financial professional and personal interests	Being part of the Women in Higher Education Network and Loughborough MAIA network to support women obtain evidence-based information on menopause symptoms and management	2020	20.03.2023	ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair in March 2023.</p> <p>Rationale: Information and support is not a specific topic that will be updated.</p>
Professor Eef Hogervorst	Co-opted member	Direct – non-financial professional and personal interests	Going through menopause increased my personal interest further as this made it more urgent to find evidence-based information to reduce symptoms and assess risk being a factor V Leiden carrier	2018	20.03.2023	ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair in March 2023.</p> <p>Rationale: Having personal experience does not preclude anyone from the discussions.</p>

Professor Eef Hogervorst	Co-opted member	Direct – non-financial professional and personal interests	<p>We give talks to the public regularly based on my previous literature reviews on HRT and brain function. One of these can be watched on the website at Lboro.ac.uk which also includes our group as a Research Focus. This website went live 12 October 2022</p> <p><a href="https://www.lboro.ac.uk/schools/sport-exercise-health-sciences/research-innovation/research-spotlights/menopause-hormones-inequality-health/">https://www.lboro.ac.uk/schools/sport-exercise-health-sciences/research-innovation/research-spotlights/menopause-hormones-inequality-health/</a></p>	12 October 2022	20.03.2023	website	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair in March 2023.</p> <p>Rationale: Whilst this is relevant to the scope of the guideline the review this was based on was not included in the evidence review and therefore the talk was not specific to the topic under discussion.</p>
Dr Gillian Reeves	Committee member	Direct - financial	Professor of Epidemiology, Director of Cancer Epidemiology Unit, Senior Scientist, University of Oxford	Interest arose more than 12 months before appointment	During recruitment	Ongoing	<p>Member's paid employment</p> <p>Declare and participate</p> <p>Agreed by GL and GC November 2022</p> <p>Rationale: Salaried employment at a University. This interest is non-specific.</p>

Dr Gillian Reeves	Committee member	Direct – non-financial professional and personal interests	I am a member of the steering committee for the Collaborative Group on Hormonal Factors in Breast Cancer. This international collaboration has carried out a pooled reanalysis of the worldwide evidence on menopausal hormone therapy and breast cancer risk, which was published in the Lancet in 2019. The findings will be submitted as evidence publication to the advisory committee.	1992	17.03.2022	Ongoing	<p>Declare and participate but not lead Topic Groups or take part in initial drafting of recommendations in topics where research the member is involved in forms part of the evidence base, answers questions rather than takes part in drafting recommendations.</p> <p>Agreed by developer Guideline Lead and NICE Guideline Commissioning Manager in May 2022.</p> <p>Rationale: Specific to the guideline, but expertise is required by the committee. Due to the overlap with the guideline, a decision was taken that the member should not lead Topic Groups or take part in initiating recommendations in</p>
-------------------	------------------	--	---	------	------------	---------	--

							topics where research the member is involved in forms part of the evidence base and should rather answer questions related to the evidence.
Dr Gillian Reeves	Committee member	Direct – non-financial professional and personal interests	I am a member of the steering committee for the Collaborative Group on Epidemiological Studies of Ovarian Cancer. This international collaboration conducted a pooled reanalysis of the worldwide evidence on menopausal hormone therapy and ovarian cancer risk, which was published in the Lancet in 2015. The findings will be submitted as evidence publication to the advisory committee.	1999	17.03.2022	Ongoing	<p>Declare and participate but not lead Topic Groups or take part in initial drafting of recommendations in topics where research the member is involved in forms part of the evidence base, answers questions rather than takes part in drafting recommendations.</p> <p>Agreed by developer Guideline Lead and NICE Guideline Commissioning Manager in May 2022.</p> <p>Rationale: Specific to the guideline, but</p>

							expertise is required by the committee. Due to the overlap with the guideline, a decision was taken that the member should not lead Topic Groups or take part in initiating recommendations in topics where research the member is involved in forms part of the evidence base and should rather answer questions related to the evidence.
Dr Gillian Reeves	Committee member	Direct – non-financial professional and personal interests	I am Principal Investigator for The Million Women Study, a large UK cohort study of women’s health. This study has published a number of high profile scientific papers on the relationship between menopausal hormone therapy and female cancers (including breast, ovarian and endometrial cancer) and hip fracture. These findings will form part of the evidence base for the advisory committee.	1996	17.03.2022	Ongoing	Declare and participate but not lead Topic Groups or take part in initial drafting of recommendations in topics where research the member is involved in forms part of the evidence base, answers questions rather than takes

							<p>part in drafting recommendations.</p> <p>Agreed by developer Guideline Lead and NICE Guideline Commissioning Manager in May 2022.</p> <p>Rationale: Specific to the guideline, but expertise is required by the committee. Due to the overlap with the guideline, a decision was taken that the member should not lead Topic Groups or take part in initiating recommendations in topics where research the member is involved in forms part of the evidence base and should rather answer questions related to the evidence.</p>
Dr Gillian Reeves	Committee member	Direct – non-financial professional	In my capacity as Director of Cancer Epidemiology Unit, University of Oxford, I lead a	2019	17.03.2022	Ongoing	Declare and participate but not lead Topic Groups

		and personal interests	broad programme of research on risk factors for common diseases among women. This research includes investigation of the role of menopausal hormone therapy in the development of conditions such as dementia and cancer, and the impact of such therapy on mammographic screening efficacy.				<p>or take part in initial drafting of recommendations in topics where research the member is involved in forms part of the evidence base, answers questions rather than takes part in drafting recommendations.</p> <p>Agreed by developer Guideline Lead and NICE Guideline Commissioning Manager in May 2022.</p> <p>Rationale: Specific to the guideline, but expertise is required by the committee. Due to the overlap with the guideline, a decision was taken that the member should not lead Topic Groups or take part in initiating recommendations in topics where research the member is involved</p>
--	--	------------------------	--	--	--	--	---

							in forms part of the evidence base and should rather answer questions related to the evidence.
Dr Gillian Reeves	Committee member	Direct – non-financial professional and personal interests	Europa Donna UK Symposium talk – to include presentation of findings on MHT use and female cancers from the Million Women Study and published meta-analyses	19.10.2022	21.10.2022	19.10.2022	<p>Declare and participate but not lead Topic Groups or take part in initial drafting of recommendations in topics where research the member is involved in forms part of the evidence base, answers questions rather than takes part in drafting recommendations.</p> <p>Agreed by developer Guideline Lead – October 2022.</p> <p>Rationale: Specific to the guideline, but expertise is required by the committee. Due to the overlap with the guideline, a decision was taken that the member</p>

							should not lead Topic Groups or take part in initiating recommendations in topics where research the member is involved in forms part of the evidence base and should rather answer questions related to the evidence.
Mr Haitham Hamoda	Topic advisor	Employment	Consultant Gynaecologist, Subspecialist in Reproductive Medicine and Surgery, Clinical Lead for the Menopause Services, Clinical Lead for Ambulatory Gynaecology Services, King's College Hospital, London	Interest arose more than 12 months before appointment	During recruitment	Ongoing	Member's paid employment Declare and participate Agreed by GL and GC November 2022 Rationale: Salaried employment in the NHS. This interest is non-specific.
Mr Haitham Hamoda	Topic advisor	Direct – financial	I carry out private clinical work in my non-NHS time for menopause, infertility and general gynaecological patients, mirrors NHS work expect for a testosterone product which is not available in the NHS.	2012	08.09.2021	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.

							Rationale: Partially specific to the guideline but unlikely to influence recommendation development and benefits outweigh the risks.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Chair of the British Menopause Society	July 2019	08.09.2021	July 2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: Mr Hamoda represents himself in the committee and not the BMS. Two Topic Advisors were appointed to bring balance to the views and discussions.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	First author of The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women	2020	08.09.2021	N/A	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical</p>

							<p>Advisor at recruitment.</p> <p>Rationale: BMS guidance way differ from NICE guideline conclusions. At interview Mr Hamoda stated that if NICE guideline conclusions will contradict BMS guidance, BMS will update their guidance.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Author of The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency	2017	08.09.2021	N/A	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: Existing POI section of the guideline retained and will not be updated.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional	Member of the Government Menopause Taskforce	03.02.2022	16.05.2022	Ongoing	Declare and participate.

		and personal interests					<p>Agreed by developer Guideline Lead in May 2022.</p> <p>Rationale: The member has declared that his involvement in the Government Menopause Taskforce will be independent of his work in the NICE guideline committee and even if the two groups' conclusions would differ, he will sign up to the conclusions made up by the NICE guideline committee.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Member of the NHSE Menopause Programme Clinical Reference Group	26.05.2021	16.05.2022	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in May 2022.</p> <p>Rationale: The member has declared that his involvement in the NHSE Menopause Programme Clinical Reference Group</p>

							will be independent of his work in the NICE guideline committee and even if the two groups' conclusions would differ, he will sign up to the conclusions made up by the NICE guideline committee.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Advisor to European Menopause and Andropause Society	08.09.2021	16.05.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead in May 2022. Rationale: Although broadly related to the topic, this interest is not specific to the guideline scope and does not pose a conflict of interest.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	I have provided comments and interviews to press, radio and TV regarding menopause matters. These have not included any reference to the NICE guidance update and have not involved any financial reimbursements.	2017	16.05.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead in May 2022.

							Rationale: Forms part of his role as the president of BMS and expert on the topic. Not specific to guideline scope.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Author of commissioned Editorial by the BMJ: Looking at HRT in perspective: Helping women make informed choices. June 2022.	June 2022	14.06.2022	N/A	<p>Declare and participate but avoid commenting on issues related to the scope of the guideline update in public going forward whilst the guideline project is ongoing. Otherwise, there may be a need to partially exclude him from decision making.</p> <p>Agreed by developer Guideline Lead and Committee Chair and QA team in July 2022.</p> <p>Rationale: The BMJ article refers to topics covered in the scope, such as evidence on the effect of HRT on all-</p>

							cause mortality and breast cancer risk. His involvement as one of the two topic advisors is important in the guideline process so on balance there is no need for action, however, he has been asked to no longer comment on topics specific to the scope in public.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Have given several media comments including the BBC and the Guardian on menopause related media queries.	Ongoing	14.06.2022	Ongoing	<p>Declare and participate but avoid commenting on issues specific to the scope of the guideline update in public going forward. Otherwise, there may be a need to partially exclude him from decision making.</p> <p>Agreed by developer Guideline Lead and Committee Chair and QA team in July 2022.</p>

							<p>Rationale: Comments made are mainly not specific to topics covered in the guideline scope but he has been asked not to make public comments around issues that are specific to the scope going forward.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Interview with ITV Breakfast regarding the recently published House of Commons Report on Menopause.	28 <sup>th</sup> July 2022	29.07.2022	28 <sup>th</sup> July 2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair August 2022.</p> <p>Rationale: This interview was focused on the impact of the Menopause on a woman’s professional life and career. Whilst this is related to symptoms of the Menopause, hormone replacement therapy and the long-term</p>

							benefits and risks were not the focus.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Interview with BBC Radio Leicester regarding the recently published Government’s Women’s Health Strategy.	28 <sup>th</sup> July 2022	29.07.2022	28 <sup>th</sup> July 2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair August 2022.</p> <p>Rationale: The Government’s Women’s Health Strategy lists Menopause as one of the priority areas. However the brief for this is broad (including access to services and education) so the interview did not include any specific recommendations related to matters in the scope of the guideline.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	ITN menopause feature for World Menopause Day	18.10.2022	21.10.2022	18.10.2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and</p>

							<p>Committee Chair November 2022.</p> <p>Rationale: The interview did not include any specific details related to matters in the scope of the guideline.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Menopause in the workplace podcast for ACAS	18.10.2022	21.10.2022	18.10.2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair November 2022.</p> <p>Rationale: The interview was on a topic that was not specific to the scope of the guideline.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Review article: Androgens in postmenopausal women. The Obstetrician and Gynaecologist October 2022 Edition.	August 2022 (ahead of print)	21.10.2022	October 2022 Journal Edition	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair November 2022.</p> <p>Rationale: The interview was on a topic that was not</p>

							specific to the scope of the guideline.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	I did two radio interviews for the BBC for World Menopause Day.	October 2022	21.10.2022	October 2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair November 2022.</p> <p>Rationale: The interviews did not include any specific details related to matters in the scope of the guideline.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Talk to metropolitan police on menopause in the workplace on national inclusion day.	26.09.2022	21.10.2022	26.09.2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair November 2022.</p> <p>Rationale: The talk was on a topic that was not specific to the scope of the guideline.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional	Joint position statement by the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for	May/June 2022	2.11.2022	September 2022	<p>Declare and participate</p> <p>Agreed by the developer GL and</p>

		and personal interests	<p>Endocrinology on best practice recommendations for the care of women experiencing the menopause</p> <p>Published in Post Reproductive Health Journal June / September 2022</p> <p>Published in Clinical Endocrinology Journal May 2022.</p>				<p>Committee Chair at recruitment – November 2022</p> <p>Rationale: This position statement includes matters directly related to the scope. It is a joint statement by several societies. Decision in these cases are made by consensus rather than reflection each individual member’s opinion.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	<p>Accompanying Editorial Published in Post Reproductive Health Journal June 2022</p> <p>Optimising the menopause transition: Joint position statement by the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on best practice recommendations for the care of women experiencing the menopause</p>	June 2022	2.11.2022	June 2022	<p>Declare and participate</p> <p>Agreed by the developer GL and Committee Chair at recruitment – November 2022</p> <p>Rationale: This editorial makes statements related to matters directly in the scope of this guideline and takes a position on these. However, it is reflecting the position of the</p>

							<p>organisation he is representing rather than personal views.</p> <p>This declared interest will be revisited when the relevant evidence is being discussed.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Response to letter to the Editors in Chief Post Reproductive Health in response to the statement above (in preparation).	October 2022	2.11.2022	October 2022	<p>Declare and participate</p> <p>Agreed by the developer GL and Committee Chair at recruitment – November 2022</p> <p>Rationale: This editorial makes statements related to matters directly in the scope of this guideline and takes a position on these. However, it is reflecting the position of the organisation he is representing rather than personal views.</p>

							This declared interest will be revisited when the relevant evidence is being discussed.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Co-author: Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society	September 2022	2.11.2022	September 2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair November 2022.</p> <p>Rationale: This pathway is broader than the scope and reflects the position taken by a society rather than an individual.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Co-author on European Menopause and Andropause Society (EMAS) position statement: Vitamin D and menopausal health	December 2022	09.01.2023	December 2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair January 2023.</p> <p>Rationale: This is not specific to the scope of the guideline.</p>

Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Quote in article in the Telegraph: Private menopause clinics prescribing HRT at 'twice the recommended dose'  'Unorthodox prescribing' of oestrogen places women at higher risk of cancer and vaginal bleeding	19.12.2022	09.01.2023	19.12.2022	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair January 2023.  Rationale: A quote in favour of prescribing in line of licensing is not prejudicial of the guideline content.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Quote in article in the Sun MENOPAUSE MATTERS Urgent warning as some women prescribed HRT which 'increases' risk of deadly cancers – are you affected?	19.12.2022	09.01.2023	19.12.2022	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair January 2023.  Rationale: Whilst this is related to the scope, the quote was very broad and did not express a clear opinion that could be viewed as prejudicial to the guideline content.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional	Facilitator and speaker at BMS PPMC training course  Talk on hormones and the breast	06.12.2022	10.01.2023	06.12.2022	Declare and participate.

		and personal interests					<p>Agreed by developer Guideline Lead and Committee Chair January 2023.</p> <p>Rationale: This was a training course rather than an opportunity to express personal opinions on the matter under discussion.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	<p>Chair and speaker at the BMS Women’s Health Annual Symposium Dec 2022 Meeting</p> <p>Talk on Endometriosis and menopause</p>	01.12.2022	10.01.2023	01.12.2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair January 2023.</p> <p>Rationale: This is not specific to the scope of the guideline.</p>
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	<p>Comment in the Mail on Sunday due to be published 15<sup>th</sup> January on demand on menopause services in the UK.</p>	January 2023	12.01.2023	15.01.2023	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair January 2023.</p> <p>Rationale: Service organisation is not</p>

							specific to the scope of the guideline.
Mr Haitham Hamoda	Topic advisor	Direct – non-financial professional and personal interests	Comment in the Guardian on menopause care and provision	February 2023	20.03.2023	February 2023	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair February 2023.</p> <p>Rationale: The comment was not specific to the topics of the update.</p>
Ms Hayley Berry	Committee member	Direct - financial	<p>Regional Manager Centre for Pharmacy Postgraduate Education (CPPE) University of Manchester</p> <p>Menopause specialist clinical pharmacist, Newson Health, Stratford-upon-Avon</p>	Interest arose more than 12 months before appointment	During recruitment	Ongoing	<p>Member's paid employment</p> <p>Declare and participate</p> <p>Agreed by developer GL and committee Chair November 2022</p> <p>Rationale: Salaried employment in a private Menopause Clinic. Not anticipated that private practice employment would influence guideline recommendations or involvement in</p>

							guideline committee unlikely to bring financial benefit to the member. Benefits of involvement outweigh the potential risks.
Ms Hayley Berry	Committee member	Direct – financial	Employed by Newson Health private menopause clinic as a menopause specialist pharmacist.	May 2021	07.03.2022	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: Paid employee on a part time basis (1 day a week) in a private menopause clinic but has years of experience from NHS primary care until December 2021. Not anticipated that private practice employment would influence guideline recommendations or involvement in guideline committee</p>

							unlikely to bring financial benefit to the member. Benefits of involvement outweigh the potential risks.
Ms Hayley Berry	Committee member	Direct – financial	Director of Hayley Berry Limited- private company providing pharmacy services including consultancy work not linked to menopause in any way.	September 2016	07.03.2022	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: Not menopause-related and limited to once a month locum work in community pharmacies.</p>
Ms Hayley Berry	Committee member	Direct – non-financial professional and personal interests	<p>As part of my role at Newson Health I am involved in the Newson Health Menopause Society as a pharmacist member and have recently done this podcast about the pharmacists role in the menopause</p> <p><a href="https://www.nhmenopausesociety.org/resources/podcast-episode-7/">https://www.nhmenopausesociety.org/resources/podcast-episode-7/</a></p>	September 2021	23.05.2022	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in May 2022.</p> <p>Rationale: Part of her job role, podcast topic not specific to topics covered in the</p>

							scope of the guideline.
Ms Hayley Berry	Committee member	Direct – non-financial professional and personal interests	I co-wrote this article for HRT shortages <a href="https://viewer.joomag.com/nursing-in-practice-summer-2022/0708699001655460564?short&amp;">https://viewer.joomag.com/nursing-in-practice-summer-2022/0708699001655460564?short&amp;</a> article on page 32	June 2022	14.06.2022	June 2022	Declare and participate. Agreed by developer Guideline Lead in June 2022. Rationale: Topic not related to the scope of the guideline update.
Ms Hayley Berry	Committee member	non-financial professional and personal interests	Case based discussion on NHMS linked to a patient- one off evening 45 min online case presentation for one of my clinic patients	28.09.2022	21.10.2022	28.09.2022	Declare and participate Agreed by developer GL and committee Chair November 2022 Rationale: The presentation is related to one person's condition and is therefore not specific to the scope of the guideline.
Ms Hayley Berry	Committee member	non-financial professional and personal interests	World menopause day presentation at Leeds university on the role of a pharmacist in menopause care and discussion board- Leeds staff only	18.10.2022	21.10.2022	18.10.2022	Declare and participate Agreed by developer GL and committee

							Chair November 2022  Rationale: The presentation is related to menopause as a broad topic and did not make specific statements about matters directly within the scope of the guideline.
Jenny Van Heerden	Co-opted member	Direct - financial	Consultant Clinical Psychologist, University College London Hospitals, Women's Health Division, London	Interest arose more than 12 months before appointment	During recruitment	Ongoing	Member's paid employment  Declare and participate  Agreed by developer GL and committee Chair November 2022  Rationale: Salaried employment in the NHS. This interest is non-specific.
Jenny Van Heerden	Co-opted member	Direct – financial	I am a Consultant Clinical Psychologist and do a small amount of private work alongside my NHS job. In my private practice I offer general psychological therapy (adult	2013	15.06.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead in September 2022.

			mental health) and do not specialize in treating menopause, although it is possible that this will occasionally be an issue for a patient I am working with. To date I have never given a private patient a focused treatment for difficulties relating to menopause.				Rationale: Private practice is not specifically related to Menopause.
Jenny Van Heerden	Co-opted member	Direct – non-financial professional and personal interests	I work as a Consultant Clinical Psychologist in the NHS (University College London Hospitals). I work in the gynaecological oncology service and assess and treat women who are experiencing psychological distress in relation to their cancer. This includes symptoms of treatment-induced menopause. I use cognitive behavioural therapy and other evidence-based approaches.	2014	15.06.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead in September 2022. Rationale: The committee member's job has a general focus on gynaecological oncology including symptoms of menopause related to treatment, but there is no scope for direct gain from the committee's work.
Jenny Van Heerden	Co-opted member	Indirect	I occasionally recommend published self-help books to patients regarding using cognitive behavioural therapy for menopause – e.g. books by	2014	15.06.2022	Ongoing	Declare and participate.

			Professor Myra Hunter. I have no personal relationship with her.				Agreed by developer Guideline Lead in September 2022.  Rationale: Even though the books may recommended a particular approach, there is no scope for direct financial gain for the committee member from the committee's work.
Jenny Van Heerden	Co-opted member	Direct – non- financial professional and personal interests	In the past I have run group- based cognitive behavioural therapy for menopause to patients who have had gynecological oncology treatment. This programme was developed by Professor Myra Hunter. I have no personal relationship with her.	2014	15.06.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead in September 2022.  Rationale: The committee member's job has a general focus on gynaecological oncology including symptoms of menopause related to treatment, but there is no scope for direct gain from the committee's work.

John Stevenson	Co-opted member	Direct - financial	Consultant Physician, Royal Brompton Hospital			Ongoing	Member's paid employment Declare and participate Agreed by developer Guideline Lead and Committee Chair November 2022 Rationale: Salaried employment in the NHS.
John Stevenson	Co-opted member	Direct - financial	Private practice – This consists of approximately 2 sessions per month. They are exactly the same as NHS clinical sessions, comprising patients with coronary heart disease risk factors, microvascular angina, metabolic risks for coronary disease, menopausal heart and bone problems (relevant to the scope of the guidelines), and general endocrinology.	20/03/22	20.03.2023	ongoing	Declare and participate. Agreed by developer Guideline Lead and Committee Chair March 2023. Rationale: Not anticipated that private practice employment would influence guideline recommendations or involvement in guideline committee unlikely to bring financial benefit to the member. Benefits of involvement as a co-

							opted member with this particular expertise outweigh the potential risks.
John Stevenson	Co-opted member	Direct - financial	Lecture: The impact of HRT on cardiovascular risk. Kyiv Ukraine. Honorarium from Abbott	17/02/23	20.03.2023	17/02/23	<p>Partial exclusion from the cardiovascular topic (included in the discussion for clarification but excluded from decision making)</p> <p>Agreed by developer Guideline Lead and Committee Chair in March 2023.</p> <p>Rationale: This is directly relevant to the scope and the honorarium is from Abbott which is a company that produces directly applicable products.</p>
John Stevenson	Co-opted member	Direct - financial	Lecture: The impact of HRT on cardiovascular risk. Astana, Kazakhstan. Honorarium from Abbott	21/02/23	20.03.2023	21/02/23	<p>Partial exclusion from the cardiovascular topic (included in the discussion for clarification but</p>

							<p>excluded from decision making)</p> <p>Agreed by developer Guideline Lead and Committee Chair in March 2023.</p> <p>Rationale: This is directly relevant to the scope and the honorarium is from Abbott which is a company that produces directly applicable products.</p>
John Stevenson	Co-opted member	Direct - financial	Advisory Board, Abbott	28/02/23	20.03.2023	28/02/23	<p>Partial exclusion from the cardiovascular topic (included in the discussion for clarification but excluded from decision making)</p> <p>Agreed by developer Guideline Lead and Committee Chair in March 2023.</p> <p>Rationale: Abbott is a company that</p>

							produces directly applicable products.
John Stevenson	Co-opted member	Direct - financial	Lecture: The impact of HRT on cardiovascular risk. Tashkent, Uzbekistan. Honorarium from Abbott	03/03/23	20.03.2023	03/03/23	<p>Partial exclusion from the cardiovascular topic (included in the discussion for clarification but excluded from decision making)</p> <p>Agreed by developer Guideline Lead and Committee Chair in March 2023.</p> <p>Rationale: This is directly relevant to the scope and the honorarium is from Abbott which is a company that produces directly applicable products.</p>
John Stevenson	Co-opted member	Direct – non-financial professional and personal interests	Chairman, Women’s Health Concern	20.03.2023	20.03.2023	ongoing	<p>Declare and participate</p> <p>Agreed by developer GL and committee Chair March 2023</p>

							Rationale: This is not specific to the guideline's scope for this update.
John Stevenson	Co-opted member	Direct – non-financial professional and personal interests	Trustee, British Menopause Society	20.03.2023	20.03.2023	ongoing	Declare and participate Agreed by developer GL and committee Chair March 2023 Rationale: This is not specific to the guideline's scope for this update.
John Stevenson	Co-opted member	Direct – non-financial professional and personal interests	Executive Committee Member, International Society of Gynecological Endocrinology	20.03.2023	20.03.2023	ongoing	Declare and participate Agreed by developer GL and committee Chair March 2023 Rationale: This is not specific to the guideline's scope for this update.
Karina Bowkett	Lay member		<i>Nothing to declare</i>				
Ms Kathy Abernethy	Committee member	Direct - financial	Director of Menopause Services, Peppy Health, London	Interest arose more than 12 months	During recruitment	Ongoing	Member's paid employment Declare and participate

				before appointment			<p>Agreed by developer GL and committee Chair November 2022</p> <p>Rationale: This salaried employment would not affect the committee member's ability to objectively consider the evidence under review. There would not be any financial gain associated with committee membership or the outcome of recommendations.</p>
Ms Kathy Abernethy	Committee member	Direct – financial	I am a paid employee of a digital health menopause service, delivering free and personalised menopause care through employers and insurers. My role is clinical, leading a team of nurses, creating clinical content and ensuring we meet regulatory requirements e.g., Nursing and Midwifery Council, ICO, consent	2018	10.02.2022	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: Currently paid employee in a private digital menopause clinic. According to the member, private</p>

							practice work/treatment decisions mirror her work as a specialist menopause nurse in the NHS (where she worked until 2020). Not anticipated that private practice employment would influence guideline recommendations or involvement in guideline committee unlikely to bring financial benefit to the member. Benefits of involvement outweigh the potential risks.
Ms Kathy Abernethy	Committee member	Direct – financial	I have a small private menopause practice of around 300 patient appointments/year	2018	10.02.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: At interview, declared that her own private practice work

							accounts for 1-2 days a month and mirrors her previous NHS work. Not anticipated that private practice employment would influence guideline recommendations or involvement in guideline committee unlikely to bring financial benefit to the member. Benefits of involvement outweigh the potential risks.
Ms Kathy Abernethy	Committee member	Direct – non-financial professional and personal interests	Trustee and Medical Advisory Council Member British Menopause Society	1997	10.02.2022	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: The member represents herself and not the BMS in the committee. Benefits of involvement</p>

							outweigh the potential risks.
Ms Kathy Abernethy	Committee member	Direct – non-financial professional and personal interests	Member of the NHSE Menopause Programme Clinical Reference Group	March 2021	16.05.2022	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in May 2022.</p> <p>Rationale: The member has declared that her involvement in the NHSE Menopause Programme Clinical Reference Group will be independent of her work in the NICE guideline committee and even if the two groups' conclusions would differ, she will sign up to the conclusions made up by the NICE guideline committee.</p>
Ms Kathy Abernethy	Committee member	Direct – non-financial professional and personal interests	In my job role, working with employers, I regularly speak to members of the public and the media around the topic of menopause, in particular	2018	16.05.2022	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in May 2022.</p>

			symptoms, treatment options and how to access support.				Rationale: This is part of her professional role in the digital health menopause service and whilst some topics may overlap with topics that are within the scope of the guideline, but the benefits of involvement outweigh the potential risks.
Ms Kathy Abernethy	Committee member	Direct – non-financial professional and personal interests	Speaker and recorded webinar for Royal Osteoporosis Society on the topic of HRT, discussing types, indications, side effects, benefits and risk	02.02.2023	14.02.2023	02.02.2023	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair February 2023.</p> <p>Rationale: Whilst this is relevant to the scope of the guideline the focus was related to osteoporosis which is one of many outcomes considered only in the 40 to 44 year olds.</p>

Kerry Barnett	Committee member (until December 2022)	Direct - financial	Advanced Nurse Practitioner, Bridges Medical Practice, Trinity Medical Centre, Gateshead, Tyne and Wear	Interest arose more than 12 months before appointment	During recruitment	Ongoing	Member's paid employment Declare and participate Agreed by developer GL and committee Chair November 2022 Rationale: Salaried employment in the NHS. This interest is non-specific.
Dr Louise Massey	Committee member	Direct, financial	Consultant in Sexual and Reproductive Health Aneurin Bevan University Health Board, Gwent	Interest arose more than 12 months before appointment	During recruitment	Ongoing	Member's paid employment Declare and participate Agreed by developer GL and committee Chair November 2022 Rationale: Salaried employment in the NHS. This interest is non-specific.
Dr Louise Massey	Committee member	Direct, financial	Medicines for Women's Health Expert Advisory Group. I am a paid member of this committee as an expert advisor	01.12.2022	05.01.2023	Ongoing	Declare and participate

							<p>Agreed by developer GL and committee Chair January 2023</p> <p>Rationale: So far the topic of HRT has not been discussed and the committee member will recuse herself if HRT would be on the agenda.</p>
Lorraine Griffiths	Lay member	Direct – financial	Self-employed Performance Coach working in the Pharmaceutical/Medical Devices Sales Industry.	2016	08.03.2022	ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: Not specific to guideline.</p>
Lorraine Griffiths	Lay member	Direct – non-financial professional and personal interests	Volunteer for Breast Cancer Now – working on the Someone Like Me telephone service/speaking with breast cancer patients and other concerned individuals	2021	08.03.2022	ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: Not specific to guideline.</p>

Professor Martha Hickey	Topic advisor	Direct, financial	<p>Consultant in Gynaecology, Head of Menopause Unit, Clinical Lead Gynaecology Research Centre, Royal Women's Hospital, Victoria, Australia</p> <p>Professor of Obstetrics and Gynaecology, Deputy Head of Department, University of Melbourne, Australia</p>	Interest arose more than 12 months before appointment	During recruitment	Ongoing	<p>Member's paid employment</p> <p>Declare and participate</p> <p>Agreed by developer GL and committee Chair November 2022</p> <p>Rationale: Salaried employment in the public sector. This interest is non-specific.</p>
Professor Martha Hickey	Topic advisor	Indirect	My organization (University of Melbourne) received funding from the commercial sector (QUE Oncology) for research into a nonhormonal treatment for menopausal symptoms. I was the site lead for this research. There was no personal payment and no publication.	2018	25.10.2021	2019	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: Unlikely relevant to topics covered in the guideline update.</p>
Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	I am Deputy Head of the Department of Obstetrics and Gynaecology at Uni Melbourne	2019	25.10.2021	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical</p>

							<p>Advisor at recruitment.</p> <p>Rationale: Not specific to guideline topic.</p>
Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	I am a site investigator in a clinical trial of a device to treat vaginal dryness in postmenopausal women (Madorra)	2020	25.10.2021	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: The device Madorra is unlikely to be specific to any evidence reviews in the guideline update.</p>
Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	<p>In 2016 I published a letter in the BMJ in response to the NICE menopause guidelines. This was co-authored with a prominent epidemiologist with an interest in breast cancer (Emily Banks). We raised several concerns about the conclusions of the guidelines <a href="https://doi.org/10.1136/bmj.i191">https://doi.org/10.1136/bmj.i191</a></p> <p>Members of the guidelines committee then responded to our letter.</p>	2016	25.10.2021	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: Having expressed views about the existing NICE guideline does not pose a conflict of</p>

							interest as such. Two Topic Advisors were appointed to bring balance to the views and discussions.
Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	I represent Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) on a national Women’s Health Committee	2020	25.10.2021	N/A	Declare and participate.  Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: Not specific to guideline.
Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	Lead investigator in the COMMA Core Outcomes in Menopause project, an international collaboration which aims to develop and disseminate Core Outcome Sets for research in menopause. <a href="https://medicine.unimelb.edu.au/school-structure/obstetrics-and-gynaecology/research/COMMA">https://medicine.unimelb.edu.au/school-structure/obstetrics-and-gynaecology/research/COMMA</a>	2016	25.10.2021	N/A	Declare and participate.  Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: Related to the guideline but unlikely to influence recommendation development and benefits outweigh the risks.

Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	Presentation at a Grand Rounds at Mater Hospital Dublin on “Empowering women to manage menopause”	24.05.2022	16.05.2022	N/A	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in May 2022.</p> <p>Rationale: Topics may overlap with topics in the guideline scope but does not pose a conflict of interest and is part of the member’s professional role.</p>
Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	<p>Analysis paper published in the BMJ:</p> <p>Hickey M, Hunter M S, Santoro N, Ussher J. Normalising menopause BMJ 2022; 377 :e069369 doi: <a href="https://doi.org/10.1136/bmj-2021-069369">https://doi.org/10.1136/bmj-2021-069369</a></p>	16.06.2022	14.06.2022	N/A	<p>Declare and participate but avoid commenting on issues specific to the scope of the guideline update in public going forward whilst the guideline project is ongoing. Otherwise, there may be a need to partially exclude her from decision making.</p> <p>Agreed by developer Guideline Lead and Committee Chair</p>

							<p>and QA team in July 2022.</p> <p>Rationale: Whilst the the BMJ article is largely outside the scope of the guideline, it refers to the effectiveness of CBT on managing symptoms associated with the menopause which is a topic covered in the guideline update. Her involvement as one of the two topic advisors is important in the guideline process so on balance there is no need for action, however, she has been asked to no longer comment on topics specific to the scope in public.</p>
Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	I will be interviewed by a journalist for an Australian documentary on menopause (Catalyst)	16.10.2022	21.10.2022	16.10.2022	<p>Declare and participate</p> <p>Agreed by developer GL and committee Chair November 2022</p>

							Rationale: Whilst this may be directly related to the scope the committee member will be mindful about topics directly related to the scope of the guideline.
Professor Martha Hickey	Topic advisor	Indirect interest	North American Menopause Society annual conference attendance	11.10.2022	21.10.2022	15.10.2022	<p>Declare and participate</p> <p>Agreed by developer GL and committee Chair November 2022</p> <p>Rationale: This is broader than the specific topics that are updated in this guideline.</p>
Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	I am leading a priority setting partnership in menopause with the James Lind Alliance. At present we are still looking for funding	2.11.2022	2.11.2022	ongoing	<p>Declare and participate</p> <p>Agreed by developer GL and committee Chair November 2022</p> <p>Rationale: This is related to priority setting for research which is not directly related to the scope</p>

							of the update but may be related to research recommendations that may result from this update.
Professor Martha Hickey	Topic advisor	Indirect interest	International Menopause Society conference attendance and invited speaker (x4)	25.10.2022	2.11.2022	29.10.2022	<p>Declare and participate</p> <p>Agreed by developer GL and committee Chair November 2022</p> <p>Rationale: Whilst some of this was directly related to the scope the committee member was mindful about making specific statements that may be perceived as prejudicial to the outcome of the guideline.</p>
Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	Meeting with the FDA about terms and instruments used to measure menopausal symptoms	08.12.2022	05.01.2023	08.12.2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair January 2023.</p>

							Rationale: This is not specific to the scope of the guideline.
Professor Martha Hickey	Topic advisor	Direct – non-financial professional and personal interests	I have contributed (invited) to the NIHR discussion on evidence gaps in menopause (via Loomio)	December 2022	09.01.2023	Jan 2023	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair January 2023.</p> <p>Rationale: The broader topic of research priorities is outside the scope of the guideline which will focus only on the gaps that may be uncovered by the evidence reviews.</p>
Professor Martha Hickey	Topic advisor	Direct – financial	<p>Publication - <a href="https://pubmed.ncbi.nlm.nih.gov/36749915/">https://pubmed.ncbi.nlm.nih.gov/36749915/</a></p> <p>Safety and effectiveness of a novel home-use therapeutic ultrasound device for the treatment of vaginal dryness in postmenopausal women: a pilot study</p>	February 2023	24.02.2023	February 2023	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair February 2023.</p> <p>Rationale: This is did not match the inclusion criteria for the related evidence review.</p>

Professor Martha Hickey	Topic advisor	Direct – financial	<p>Publication  <a href="https://pubmed.ncbi.nlm.nih.gov/36696638/">https://pubmed.ncbi.nlm.nih.gov/36696638/</a></p> <p>Video telehealth to manage menopausal symptoms after cancer: a prospective study of clinicians and patient satisfaction</p>	February 2023	24.02.2023	February 2023	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair February 2023.</p> <p>Rationale: This is not specific to the scope of the guideline.</p>
Professor Martha Hickey	Topic advisor	Direct – financial	<p>Publication  <a href="https://pubmed.ncbi.nlm.nih.gov/36696637/">https://pubmed.ncbi.nlm.nih.gov/36696637/</a></p> <p>Priorities for alleviating menopausal symptoms after cancer</p>	February 2023	24.02.2023	February 2023	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and Committee Chair February 2023.</p> <p>Rationale: This is related to the types of symptoms women wanted to prioritise and is therefore not specific to the scope of the guideline.</p>
Professor Martha Hickey	Topic advisor	Direct – financial	<p>Publication  <a href="https://pubmed.ncbi.nlm.nih.gov/36366886/">https://pubmed.ncbi.nlm.nih.gov/36366886/</a></p> <p>Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking</p>	November 2022	24.02.2023	November 2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead, Chair February 2023.</p>

			tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial				Rationale: This is not specific to the scope of the guideline.
Professor Martha Hickey	Topic advisor	Direct – financial	Publication <a href="https://pubmed.ncbi.nlm.nih.gov/36244695/">https://pubmed.ncbi.nlm.nih.gov/36244695/</a>  Management of Menopause Symptoms and Quality of Life during the Menopause Transition	December 2022	24.02.2023	December 2022	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.
Professor Martha Hickey	Topic advisor	Direct – financial	Publication <a href="https://pubmed.ncbi.nlm.nih.gov/35933227/">https://pubmed.ncbi.nlm.nih.gov/35933227/</a>  What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy	October 2022	24.02.2023	October 2022	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.
Professor Martha Hickey	Topic advisor	Direct – financial	Publication <a href="https://pubmed.ncbi.nlm.nih.gov/35690930/">https://pubmed.ncbi.nlm.nih.gov/35690930/</a>  Menopause, hysterectomy, menopausal hormone therapy	August 2022	24.02.2023	August 2022	Declare and participate.  Agreed by developer Guideline Lead and

			and cause-specific mortality: cohort study of UK Biobank participants				Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.
Professor Martha Hickey	Topic advisor	Direct – non- financial professional and personal interests	Publications relevant to the guidelines. Two were associated with pharma <a href="https://pubmed.ncbi.nlm.nih.gov/36749915/">https://pubmed.ncbi.nlm.nih.gov/36749915/</a>  Safety and effectiveness of a novel home-use therapeutic ultrasound device for the treatment of vaginal dryness in postmenopausal women: a pilot study <a href="https://pubmed.ncbi.nlm.nih.gov/36366886/">https://pubmed.ncbi.nlm.nih.gov/36366886/</a>  Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomized, double- blind, placebo-controlled trial.	August 2022	24.02.2023	February 2023	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair February 2023.  Rationale: One of the studies did not match the inclusion criteria for the related systematic review and the other publication is on vasomotor symptoms which is not a topic that will be updated.
Nina Kuypers	Lay member	Direct – non- financial professional	Running Black Women in Menopause free events and private Facebook group. These events are to raise awareness	August 2020	07.03.2022	ongoing	Declare and participate.  Agreed by developer Guideline Lead and

		and personal interests	and provide education about perimenopause, menopause and beyond within the Black community using black professionals. The Facebook group is a support group where black women and women of colour can support each other in a safe environment.				NICE Clinical Advisor at recruitment.  Rationale: Specific to guideline but does not pose a conflict of interest.
Nina Kuypers	Lay member	Direct – financial	Writing an article for a digital menopause service highlighting how black women may have a different experience of menopause, these do not include any reference to NICE guidance update.	May 2022	08.06.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – financial	Delivered a session highlighting a Black Womans’ Menopausal experience for Zurich UK race and ethnicity network. This does not include any reference to NICE guidance updates.	May 2022	08.06.2022	May 2022	Declare and participate.  Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.

Nina Kuypers	Lay member	Direct – financial	Delivered a session highlighting a Black Womens’ Menopausal experience for TESCOs’ race and ethnicity network.	October 2021	08.06.2022	October 2021	Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – financial	Presented a talk about Race and Menopause for Aneurin Bevan UHB.	November 2021	08.06.2022	November 2021	Declare and participate.  Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	Attended a Menopause Group session organised by the APPG Menopause	April 2022	14.06.2022	April 2022	Declare and participate.  Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – non-financial professional	Presented a short talk to Women and Work APPG - Menopause in the Workplace.	March 2022	14.06.2022	March 2022	Declare and participate.

		and personal interests					Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	Panel discussion raising the awareness of menopause for ITV Wales menopause champion launch event	March 2022	14.06.2022	March 2022	Declare and participate.  Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	Menopause Mindfulness: Embracing the Change of My Midlife for SWHR. Invited to discuss my experiences and diagnosis during the menopause transition and postmenopause.	February 2022	14.06.2022	February 2022	Declare and participate.  Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – non-financial professional	Presented a short talk for Menopause Inclusion Collective - Collective Conversations Series	October 2021	14.06.2022	October 2021	Declare and participate.

		and personal interests	'A Discussion on Black Menopause'				Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	Presented a short talk to the Menopause APPG - An insight into a Black Womens Menopausal experience.	July 2021	14.06.2022	July 2021	Declare and participate.  Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	Board of Trustee - Hwupenyu Health and Wellbeing Project is a charity based in Glasgow. They provide support for Black ethnic communities in Scotland living with chronic health conditions.	November 2020	14.06.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead in June 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – non-financial professional	Panel member for BSI Menopause Workplace Guide.	June 2022	11.07.2022	Ongoing	Declare and participate.

		and personal interests					Agreed by developer Guideline Lead in September 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	Presenting a lived experience talk to the British Caribbean Doctors and Dentists Association about Black Women in Menopause.	June 2022	11.07.2022	July 2022	Declare and participate.  Agreed by developer Guideline Lead in September 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – Financial interest	Delivered a session highlighting a Black Woman’s Menopausal experience for British Association of Social Workers. This does not include any reference to NICE guidance updates.	October 2022	21.10.2022	October 2022	Declare and participate.  Agreed by developer Guideline Lead in November 2022.  Rationale: This session was not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member		Delivered a session highlighting a Black Woman’s Menopausal experience for Levelling Up	October 2022	21.10.2022	October 2022	Declare and participate.

			Government. This does not include any reference to NICE guidance updates.				Agreed by developer Guideline Lead in November 2022.  Rationale: This session was not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct – non- financial professional and personal interests	Panel member for BSI Menopause Workplace Guide.	June 2022	21.10.2022	Ongoing	Declare and participate.  Agreed by developer Guideline Lead in November 2022.  Rationale: Menopause within the workplace is outside the scope of this guideline.
Nina Kuypers	Lay member	Direct – non- financial professional and personal interests	Wrote an article for the British Association for Counselling and Psychotherapy on Black women in menopause	October 2022	21.10.2022	October 2022	Declare and participate.  Agreed by developer Guideline Lead in November 2022.  Rationale: Counselling and psychotherapy related to menopause are

							outside the scope of this guideline.
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	Featured in an article for the Stylist	October 2022	21.10.2022	October 2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in November 2022.</p> <p>Rationale: This feature was not specific to the topics covered in the guideline scope.</p>
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	Panel member for BSI Menopause Workplace Guide	June 2022	10.02.2023	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in February 2023.</p> <p>Rationale: Menopause in the workplace is not specific to the topics covered in the guideline scope.</p>
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	NHSE Menopause User Engagement Forum	23.01.2023	10.02.2023	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in February 2023.</p>

							Rationale: This interest is not specific to the topics covered in the guideline scope.
Nina Kuypers	Lay member	Direct - financial	Delivered a session highlighting a Black Woman's Menopausal experience for HSBC Government. This does not include any reference to NICE guidance updates.	13 <sup>th</sup> February 2023	15.02.2023	15 <sup>th</sup> March 2023	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.
Nina Kuypers	Lay member	Direct - financial	Delivering a session 'The menopause: It's there in black and white' for NHS Menopause Hub. This does not include any reference to NICE guidance updates.	27 <sup>th</sup> February 2023	15.02.2023	24 <sup>th</sup> March 2023	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.
Nina Kuypers	Lay member	Direct - financial	Delivering a session 'for Oxford Brookes University " The Colourless Illusion of Menopause". This does not	February 2023	15.02.2023	24th April 2023	Declare and participate.  Agreed by developer Guideline Lead and

			include any reference to NICE guidance updates.				Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	Panel member for BSI Menopause Workplace Guide.	June 2022	15.02.2023	ongoing	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.
Nina Kuypers	Lay member	Direct – non-financial professional and personal interests	MAPS - JLA PSP - Steering Group	09 <sup>th</sup> March 2023	15.02.2023	ongoing	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.
Nina Kuypers	Lay member	Direct – non-financial professional	Wrote an article for 'The Voice' Newspaper – titled 'The Colourless Menopause'. This	13 <sup>th</sup> February 2023	17.02.2023	07 <sup>th</sup> March 2023	Declare and participate.

		and personal interests	does not include any reference to NICE guidance updates.				Agreed by developer Guideline Lead and Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.
Nina Kuypers	Lay member	Direct – non- financial professional and personal interests	Interviewed and quoted in the iPaper about ‘Ethnic minority women in England far less likely to get menopause treatment, data shows’. This does not include any reference to NICE guidance updates.	10 <sup>th</sup> March 2023	17.02.2023	12 <sup>th</sup> March 2023	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.
Nina Kuypers	Lay member	Direct – non- financial professional and personal interests	Wrote a book review for ‘Black and Menopausal’ to be published in June 2023. This does not include any reference to NICE guidance updates.	10th March 2023	17.02.2023	12th March 2023	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair February 2023.  Rationale: This is not specific to the scope of the guideline.

Dr Sarah Hillman	Committee member	Direct - financial	GP, Bidford Health Centre, Bidford-upon Avon  Clinical Lecturer in Primary Care, University of Warwick	Interest arose more than 12 months before appointment	During recruitment	Ongoing	Member's paid employment Declare and participate Agreed by developer GL and committee Chair November 2022  Rationale: Salaried employment in the NHS and at University. This interest is non-specific.
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	Member of the NHSE Menopause Programme Clinical reference group	December 2021	23.02.2022	Ongoing	Declare and participate. Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.  Rationale: At recruitment, the member declared that her involvement in the NHSE Menopause Programme Clinical Reference Group will be independent

							of her work in the NICE guideline committee and even if the two groups' conclusions would differ, she will sign up to the conclusions made up by the NICE guideline committee.
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	Advisor for current project Menopause and the NHS workforce a project being undertaken by the NHS Midlands and Lancashire commissioning support unit	February 2022	23.02.2022	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead and NICE Clinical Advisor at recruitment.</p> <p>Rationale: May be broadly relevant to the guideline although unlikely to be specific to any evidence review topic in the guideline update. Unlikely to influence guideline recommendations.</p>
Dr Sarah Hillman	Committee member	Direct – non-financial professional	Board member of the West Midlands RCGP	May 2021	16.05.2022	Ongoing	Declare and participate.

		and personal interests					Agreed by developer Guideline Lead in May 2022.  Rationale: Not specific to the guideline.
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	<p>Published an article: Sarah Hillman, Saran Shantikumar, Ali Ridha, Dan Todkill, Jeremy Dale. Socioeconomic status and HRT prescribing: a study of practice-level data in England. British Journal of General Practice 2020; 70 (700): e772-e777. DOI: 10.3399/bjgp20X713045</p> <p>And based on the article was involved in Dr Louise Newson's podcast: <a href="https://thedrlouisenewsonpodcast.podbean.com/e/074-hrt-prescriptions-in-england-dr-sarah-hillman-dr-louise-newson-1605615340/">https://thedrlouisenewsonpodcast.podbean.com/e/074-hrt-prescriptions-in-england-dr-sarah-hillman-dr-louise-newson-1605615340/</a></p> <p>And took part in BJGP webinar about health inequalities where</p>	2020	16.05.2022	N/A	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in May 2022.</p> <p>Rationale: Not specific to the topics covered in the guideline scope.</p>

			<p>the paper was discussed:  <a href="https://bjgp.org/page/video">https://bjgp.org/page/video</a></p> <p>Direct link to the webinar:  <a href="https://www.youtube.com/watch?v=gVJw1Pe-ZL8&amp;t=1794s">https://www.youtube.com/watch?v=gVJw1Pe-ZL8&amp;t=1794s</a></p>				
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	Wrote a chapter in a book Cracking the menopause by Mariella Frostup and Alice Smellie. The chapter is not specific to menopause but discusses the lack of clinical evidence on women’s health in general.	2021	16.05.2022	N/A	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in May 2022.</p> <p>Rationale: Not specific to the guideline.</p>
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	Clinical Lecturer in primary care at the University of Warwick for medical students, including lectures about menopause and HRT.	March 2020	16.05.2022	Ongoing	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in May 2022.</p> <p>Rationale: Topics may overlap with topics in the guideline scope but does not pose a conflict of interest and is part of the member’s professional role.</p>

Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	I am the co-lead in the medical school (University of Warwick) for the Athena swan sub group “Women’s health and menopause” where we try to help staff. As part of this group we organised a webinar on menopause in 2020: <a href="https://warwick.ac.uk/fac/sci/med/staffintranet/wellbeing/womenshealth/virtualseminar">https://warwick.ac.uk/fac/sci/med/staffintranet/wellbeing/womenshealth/virtualseminar</a>	2020	16.05.2022	N/A	Declare and participate.  Agreed by developer Guideline Lead in May 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	Presentation at society academic primary care conference on “experiences of GPs going through the menopause	05.07.2022	11.07.2022	05.07.2022	Declare and participate.  Agreed by developer Guideline Lead in September 2022.  Rationale: Not specific to the topics covered in the guideline scope.
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	Spoken at Webinar about health inequalities including menopause care to women’s health network ICB	07.12.2022	05.01.2023	07.12.2022	Declare and participate.  Agreed by developer Guideline Lead in February 2023.  Rationale: This was a broader topic of which Menopause was only one example and

							therefore it was not specific to the scope of the guideline.
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	Took part in NIHR virtual workshop on research and menopause	05.12.2022	05.01.2023	10.12.2022	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in February 2023.</p> <p>Rationale: The broader portfolio of research priorities for the whole topic of Menopause is outside the scope of the guideline.</p>
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	Chaired research webinar on menopause for society of academic primary care	18.01.2023	19.01.2023	18.01.2023	<p>Declare and participate.</p> <p>Agreed by developer Guideline Lead in February 2023.</p> <p>Rationale: This was a general research webinar rather than specific to the scope of the guideline update.</p>
Dr Sarah Hillman	Committee member	Direct – non-financial professional	Steering committee member for BLUSH trial looking at oxybutynin	01.01.2023	15.02.2023	Ongoing	Declare and participate.

		and personal interests	for vasomotor symptoms lead Melanie Davies				Agreed by developer Guideline Lead in February 2023.  Rationale: This interest is not specific to the scope of the guideline because the update does not cover effectiveness of treatment options for vasomotor symptoms.
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	Application for grant to be submitted May 2023 HTA NIHR commissioned call for an RCT looking at testosterone use in women with menopausal symptoms other than low libido	01/01/23	20.03.2023	ongoing	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair March 2023.  Rationale: This is not specific to the scope of the guideline.
Dr Sarah Hillman	Committee member	Direct – non-financial professional and personal interests	Podcast recorded with Liz Earle re new testosterone patches and supply of HRT	03.04.2023	05.04.2023	03.04.2023	Declare and participate.  Agreed by developer Guideline Lead and Committee Chair February 2023.

								Rationale: This is not specific to the scope of the guideline.
--	--	--	--	--	--	--	--	--

**GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER**

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.